UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 319

Sortiert nach

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Annals of oncology, 2018-04, Vol.29 (4), p.959-965

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Annals of oncology, 2023-02, Vol.34 (2), p.173-185

2023

Link zum Volltext

Verfügbarkeit prüfen

Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

European journal of cancer (1990), 2014-01, Vol.50 (2), p.302-308

2014

Link zum Volltext

Verfügbarkeit prüfen

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

British journal of cancer, 2013-09, Vol.109 (5), p.1085-1092

2013

Link zum Volltext

Verfügbarkeit prüfen

Baseline tumour measurements predict survival in advanced non-small cell lung cancer

British journal of cancer, 2013-09, Vol.109 (6), p.1476-1481

2013

Link zum Volltext

Verfügbarkeit prüfen

PC02.03 IO Should Be Given as a Single Agent

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S140-S141

Brahmer, J.

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

British journal of cancer, 2009-11, Vol.101 (9), p.1543-1548

2009

Link zum Volltext

Verfügbarkeit prüfen

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

Lung cancer (Amsterdam, Netherlands), 2012-06, Vol.76 (3), p.410-415

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

British journal of cancer, 2014-02, Vol.110 (3), p.602-608

2014

Link zum Volltext

Verfügbarkeit prüfen

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2013-09, Vol.81 (3), p.416-421

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis

ESMO open, 2024-01, Vol.9 (1), p.102199-102199, Article 102199

2024

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

ESMO open, 2023-12, Vol.8 (6), p.102065-102065, Article 102065

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study

Clinical oncology (Royal College of Radiologists (Great Britain)), 2015-04, Vol.27 (4), p.187-196

2015

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néoadjuvant (Tt néoadj) du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) dans l’essai de phase 3 CheckMate 816 (CM 816)

Revue des maladies respiratoires actualités, 2022-01, Vol.14 (1), p.201-201

2022

Link zum Volltext

Verfügbarkeit prüfen

3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)

European journal of cancer (1990), 2015-09, Vol.51, p.S631-S631

2015

Link zum Volltext

Verfügbarkeit prüfen

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

European journal of cancer (1990), 2015-09, Vol.51, p.S632-S633

2015

Link zum Volltext

Verfügbarkeit prüfen

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

European journal of cancer (1990), 2015-09, Vol.51, p.S632-S632

2015

Link zum Volltext

Verfügbarkeit prüfen

CheckMate 227 : nivolumab (nivo) + ipilimumab (ipi) versus doublet de chimiothérapie à base de sels de platine (chimio) en traitement de première ligne (1L) du cancer bronchique non à petites cellules (CBNPC) avancé avec une charge mutationnelle tumorale (Tumor Mutational Burden, TMB) élevée

Revue des maladies respiratoires, 2019-01, Vol.36, p.A116-A116

2019

Link zum Volltext

Verfügbarkeit prüfen

3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)

European journal of cancer (1990), 2015-09, Vol.51, p.S599-S599

2015

Link zum Volltext

Verfügbarkeit prüfen

Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur

Revue des maladies respiratoires actualités, 2020-01, Vol.12 (1), p.208-209

2020

Link zum Volltext

Verfügbarkeit prüfen

IO Should Be Given as a Single Agent: PC02.03

Journal of thoracic oncology, 2019-10, Vol.14 (10 Suppl), p.S140-S141

Brahmer, J

2019

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors Improve Survival and Local Control in Patients With Spine Metastasis After Stereotactic Body Radiotherapy

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.e604-e605

2021

Link zum Volltext

Verfügbarkeit prüfen

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

British journal of cancer, 2010-04, Vol.102 (8), p.1311-1311

2010

Link zum Volltext

Verfügbarkeit prüfen

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Annals of oncology, 2016-10, Vol.27, p.vi328-vi328

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 319

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(305)
Mit Volltextzugriff
(300)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(118)
Life Sciences & Biomedicine
(113)
Humans
(105)
Oncology
(103)
Female
(65)
Male
(62)
Aged
(54)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(54)
Lung Neoplasms - Drug Therapy
(54)
Middle Aged
(52)
Adult
(47)
Tumors
(42)
Immunotherapy
(36)
Lung Neoplasms - Pathology
(35)
Lung Cancer
(34)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(30)
Biological And Medical Sciences
(30)
Medical Sciences
(30)
Carcinoma, Non-Small-Cell Lung - Pathology
(28)
Treatment Outcome
(28)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

Baseline tumour measurements predict survival in advanced non-small cell lung cancer

PC02.03 IO Should Be Given as a Single Agent

Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study

Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néoadjuvant (Tt néoadj) du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) dans l’essai de phase 3 CheckMate 816 (CM 816)

3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

CheckMate 227 : nivolumab (nivo) + ipilimumab (ipi) versus doublet de chimiothérapie à base de sels de platine (chimio) en traitement de première ligne (1L) du cancer bronchique non à petites cellules (CBNPC) avancé avec une charge mutationnelle tumorale (Tumor Mutational Burden, TMB) élevée

3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)

Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur

IO Should Be Given as a Single Agent: PC02.03

Immune Checkpoint Inhibitors Improve Survival and Local Control in Patients With Spine Metastasis After Stereotactic Body Radiotherapy

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Suchergebnisse filtern